ADPT · Healthcare
ADAPTIVE BIOTECHNOLOGIES CORP
Smart-money confidence
· 1 of 3 sources firing
Weak — few signals
No standout activity across the feeds we track.
Hedge funds
57
Congress
No data
Insiders
No data
Cross-source blend of hedge-fund breadth, Congress trades, and insider Form 4s. ·
how the score works
◆ Next steps
Interested in ADAPTIVE BIOTECHNOLOGIES CORP? Here's what to do with it.
◇
Compare with other stocks
Sort 7,111 stocks by confidence, holders, or Congress signal
◈
Backtest the strategy
See how the model has done historically before you commit real money
✉
Get the weekly digest
One email on Sunday · what changed in the model this week
Not financial advice. Bogen Capital surfaces public SEC filings — you decide what to do with them.
Market cap
$3.6B
Industry
Diagnostics & Research
Sector
Healthcare
Exchange
NasdaqGS
About ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers…
Who's behind the signal
Every informed buyer we can see on ADPT, across all three feeds.
Hedge funds · 10
Viking Global Investors
New position
Bridgewater Associates (Dalio)
Increased +76%
D.E. Shaw & Co
Increased +158%
Gotham Asset Mgmt (Greenblatt)
Increased +11%
Citadel Advisors
Increased +103%
ARK Invest (Cathie Wood)
Decreased −32%
+4 more in the full breakdown below ↓
Congress · 0
No congressional trades on record.
Insiders
No significant Form 4 insider activity in the window.
Not a model pick — but on our radar.
ADAPTIVE BIOTECHNOLOGIES CORP isn't in the top-10 model right now, but 10 tracked investors hold it. Everything below is real signal from public filings — treat this as a watch candidate, not a conviction call.
10
Investors
1
New positions
4
Increasing
5
Decreasing
0
Unchanged
Price History
Loading price data...
Return:
High:
Low:
Who's Holding This Stock
Position sizes and recent activity from tracked institutional investors
Trust weight: 1.5×
% of portfolio
1.3%
Position change
NEW
1.3% of Viking Global Investors's portfolio
Trust weight: 1.3×
% of portfolio
0.0%
Position change
+76%
0.0% of Bridgewater Associates's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
+158%
0.0% of D.E. Shaw & Co's portfolio
Trust weight: 1.1×
% of portfolio
0.0%
Position change
+11%
0.0% of Gotham Asset Mgmt's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
+103%
0.0% of Citadel Advisors's portfolio
Trust weight: 1.3×
% of portfolio
0.2%
Position change
−32%
0.2% of ARK Invest's portfolio
Trust weight: 1.2×
% of portfolio
0.1%
Position change
−19%
0.1% of Tudor Investment's portfolio
Trust weight: 1.1×
% of portfolio
0.0%
Position change
−36%
0.0% of Point72's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
−23%
0.0% of AQR Capital Management's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
−95%
0.0% of Millennium Management's portfolio
Portfolio Allocation
How much of each investor's portfolio is allocated to ADAPTIVE BIOTECHNOLOGIES CORP
⚠ Disclaimer: This page is for informational purposes only. Holdings data from SEC EDGAR 13F filings, delayed up to 135 days. Not a recommendation to buy or sell ADAPTIVE BIOTECHNOLOGIES CORP or any security.
Get the Weekly Update
Every Sunday, we'll send you what Buffett, Dalio, Ackman and 47 other legendary investors are buying — free, straight from their SEC filings.
Free forever · No spam · Unsubscribe anytime